LCM
NBIX icon

Landscape Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Landscape Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,684
Closed -$1M – 849
2024
Q3 		$1M Buy
+8,684
New +$1.19M 0.1% 266
2019
Q4 		– Sell
-2,389
Closed -$215K – 766
2019
Q3 		$215K Buy
+2,389
New +$223K 0.02% 585
2017
Q2 		– Sell
-10,940
Closed -$423K – 402
2017
Q1 		$423K Hold
10,940
– – 0.04% 338
2016
Q4 		$423K Buy
+10,940
New +$495K 0.06% 346

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Landscape Capital Management's NBIX Position: Q4 2024 in Review

Landscape Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 8,684 shares — an estimated $1M sold.

Landscape Capital Management first reported a position in NBIX in Q4 2016 and held it in 4 quarters. The position peaked at $1M in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Landscape Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Landscape Capital Management sold 8,684 Neurocrine Biosciences shares in Q4 2024, an estimated $1M.
  • Landscape Capital Management first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 4 quarters.
  • Landscape Capital Management's Neurocrine Biosciences position peaked at $1M in Q3 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Landscape Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.